| Aug 5 |
Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 23 |
Nuvation Bio announces updates for its ROS1 inhibitor, Taletrectinib
|
| Jul 23 |
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
|
| Jul 12 |
We Think Nuvation Bio (NYSE:NUVB) Can Easily Afford To Drive Business Growth
|
| Jun 20 |
Nuvation Bio: A Potentially Transformative Acquisition
|
| Jun 1 |
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
|
| May 29 |
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
|
